Cinchocaine-Hcl

Total Page：16

File Type：pdf, Size：1020Kb

CINCHOCAINE-HCL Your patch test results indicate that you have a contact allergy to cinchocaine-HCL. This contact allergy may cause your skin to react when it is exposed to this substance although it may take several days for the symptoms to appear. Typical symptoms include redness, swelling, itching and fluid-filled blisters. Where is cinchocaine-HCL found? Cinchocaine-HCL is an amide local anesthetic. It is the active ingredient in some topical hemorrhoid creams. How can you avoid contact with cinchocaine-HCL? Avoid products that list any of the following names in the ingredients: • Cinchocaine-HCL • C 3225 • Cincaine chloride • Cincaine hydrochloride • Cinchocaine hydrochloride • Cinchocainium chloride • EINECS 200-498-1 • Nupercainal • Nupercaine hydrochloride • Cinchocaine hydrochloride • 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide monohydrochloride • 2-Butoxy-N-(2-diethylaminoethyl)cinchoninamide hydrochloride • 2-Butoxy-N-(2-diethylaminoethyl)cinchoninic acid amide hydrochloride • 4-Quinolinecarboxamide, 2-butoxy-N-(2-(diethylamino)ethyl)-, monohydrochloride • Butoxycinchoninic acid diethylethylenediamide hydrochloride • Cinchoninamide, 2-butoxy-N-(2-(diethylamino)ethyl)-, monohydrochloride • Benzolin • Dibucaine hydrochloride • Nupercaine hydrochloride • Percaine • Sovcaine What are some products that may contain cinchocaine-HCL? Antiseptic Wash Hemorrhoid Creams Local Anesthetics: • Aloe vera with lidocaine • Antiseptic and topical analgesic • First aid spray • Vaginal/perianal pain relievers For additional information about products that might contain cinchocaine-HCL, go to the Household Product Database online (http:/ householdproducts.nlm.nih.gov) at the United States National Library of Medicine. These lists are brief and provide just a few examples. They are not comprehensive. Product formulations also change frequently. Read product labels carefully and talk to your doctor if you have any questions. These are general guidelines. Talk to your doctor for more specific instructions. FOR MORE INFORMATION ABOUT YOUR ALLERGY, VISIT contactdermatitisinstitute.com 81784_0315 © 2015 Contact Dermatitis Institute • All rights reserved.

Copy Link

Recommended publications

Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
[Show full text]
Meta-Xylene: Identification of a New Antigenic Entity in Hypersensitivity
Clinical Communications Meta-xylene: identification of a new Our patient is a 53-year-old male who presented in 2003 with antigenic entity in hypersensitivity contact dermatitis after the use of lidocaine and disinfection with reactions to local anesthetics chlorhexidine. In 2006, an extensive skin testing by patch, prick, Kuntheavy Ing Lorenzini, PhDa, intradermal sampling, and graded challenge was performed as b c followed. The patch tests were performed with the thin layer Fabienne Gay-Crosier Chabry, MD , Claude Piguet, PhD , rapid use epicutaneous test, using the caine mix (benzocaine, a and Jules Desmeules, MD tetracaine, and cinchocaine), the paraben mix (methyl, ethyl, propyl, butyl, and benzylparaben), and the Balsam of Peru. The Clinical Implications caine and paraben mix were positive, and the patch test was possibly positive for Balsam of Peru. The prick test performed The authors report a patient who presented delayed with preservative-free lidocaine 20 mg/mL (Lidocaïne HCl hypersensitivity reactions to several local anesthetics, all “Bichsel” 2%, Grosse Apotheke Dr. G. Bichsel, Switzerland) was containing a meta-xylene entity, but not to articaine, negative. The intradermal test, performed with lidocaine 20 mg/ which is a thiophene derivative. Meta-xylene could be the mL containing methylparaben (Xylocain 2%, AstraZeneca, immunogenic epitope. Switzerland) with 1/10 and 1/100 dilutions, was negative. The subcutaneous challenge test was performed with 10 mg of preservative-free lidocaine 20 mg/mL (Lidocaïne HCl “Bichsel” TO THE EDITOR: 2%, Grosse Apotheke Dr. G. Bichsel) and lidocaine 20 mg/mL containing methylparaben (Lidocaïne Streuli 2%, Streuli, Hypersensitivity reactions to local anesthetics (LAs) are rare and Switzerland), both of which were positive and had the appear- represent less than 1% of all adverse reactions to LAs.
[Show full text]
Product Monograph
PRESCRIBING INFORMATION INCLUDING PATIENT MEDICATION INFORMATION PrSANDOZ PROCTOMYXIN HC (Hydrocortisone, Framycetin Sulfate, Cinchocaine Hydrochloride and Esculin) Ointment PrSANDOZ PROCTOMYXIN HC SUPPOSITORIES (Hydrocortisone, Framycetin Sulfate, Cinchocaine Hydrochloride and Esculin) Suppositories Antibacterial – Corticosteroid – Anorectal Therapy Sandoz Canada Inc. Date of Revision 110 Rue de Lauzon November 16, 2018 Boucherville, QC J4B 1E6 Submission Control Number: 220681 PRESCRIBING INFORMATION Sandoz Proctomyxin HC Sandoz Proctomyxin HC Suppositories (Hydrocortisone, Framycetin Sulfate, Cinchocaine Hydrochloride and Esculin) Suppositories and Ointment THERAPEUTIC CLASSIFICATION Antibacterial – Corticosteroid – Anorectal Therapy ACTIONS AND CLINICAL PHARMACOLOGY Framycetin sulfate, also known as neomycin B, is an aminoglycoside antibiotic which forms the major component of neomycin sulfate and has similar actions and uses. Aminoglycosides are taken up into sensitive bacterial cells by an active transport process which is inhibited in anærobic, acidic, or hyperosmolar environments. Within the cell, they bind to the 30S and to some extent to the 50S subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of the genetic code. The manner in which cell death is brought about is imperfectly understood, and other mechanisms may contribute, including effects on membrane permeability. In general, neomycin is active against many ærobic gram-negative bacteria and some aerobic gram-positive bacteria. Bacterial strains susceptible to neomycin include: Escherichia coli, Hæmophilus influenzæ, Moraxella lacunata, indole-positive and indole-negative Proteus, Staphylococcus aureus, S. epidermidis and Serratia. Neomycin is only minimally active against streptococci. Pseudomonas æruginosa is generally resistant to the drug. The drug is inactive against fungi, viruses, and most anærobic bacteria. Natural and acquired resistance to neomycin have been demonstrated in both gram-negative and gram-positive bacteria.
[Show full text]
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
[Show full text]
Contact Dermatitis to Medications and Skin Products
Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
[Show full text]
EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
[Show full text]
WO 2008/034819 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 27 March 2008 (27.03.2008) WO 2008/034819 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K9/00 (2006.01) A61K 31/16 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/18 (2006.01) AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, (21) International Application Number: ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, PCT/EP2007/059827 IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (22) International Filing Date: MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, 18 September 2007 (18.09.2007) PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 06121 134.8 22 September 2006 (22.09.2006) EP ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): PHAR- European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, MATEX ITALIA SRL [IT/IT]; Via Andrea Appiani, 2, FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, 1-20121 Milano (IT).
[Show full text]
Estonian Statistics on Medicines 2013 1/44
Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
[Show full text]
The Baboon Syndrome After Cinchocaine Ointment
MOJ Clinical & Medical Case Reports Case Report Open Access The baboon syndrome after cinchocaine ointment Case report 1 Volume 10 Issue 5 - 2020 A 48-year-old man presented with progressive, intense perianal Ilario Froehner Junior erythematous area after an initial 3-day period of topical cream Colorectal Surgeon at University of Sao Paulo, Nossa Senhora ointment application, composed of cinchocaine and policresulen, in das Graças Hospital, Brazil order to treat haemorrhoids. He complained of a progressive reddish area comprising from the middle sacral third to the greater trochanter Correspondence: Ilario Froehner Junior, Colorectal Surgeon at University of Sao Paulo, chairman of the Gastrointestinal of the femur, bilaterally, to the inner part of the proximal thighs. Motility Laboratory at Nossa Senhora das Graças Hospital, The patient denied any systemic symptom, just local discomfort Brazil, Tel +55 41 99684 5645, and pruritus. He used a towel to retain the significant amount of Email transudation formed, turning his chair wet. There was no infectious Received: September 04, 2020 | Published: September 15, signs. Digital rectal examination was uneventful and the anal canal 2020 had no alterations. Patient confirmed not applying the ointment into the anal canal. Case report 2 cetoprofene, hydrocortisone and intramuscular prometazine, with moderate symptoms relief. After two weeks, a 49-year-old male patient complained of perianal discomfort associated with a 7-day progressive local Suspension of cinchocaine and policresulen topic ointment was hyperemia after topical use of cinchocaine and policresulen ointment advised, associated with prednisone and fexofenadine oral intake in order to treat a thrombosed external haemorrhoid. He denied fever and topic nistatin plus zinc oxide ointment, 3 times a day or after or other systemic symptoms, just reporting pruritus and local intense evacuation.
[Show full text]
Caine Mix [A] | Allergeaze Contact Dermatitis Allergens
7-7-2020 Caine mix [A] | allergEAZE Contact Dermatitis Allergens Caine mix [A] CAS#: 94-09-7, 61-12-1, 136-47-0 Where is this allergen found? Caine mix [A] contains three anaesthetics for topical use: benzocaine, dibucaine hydrochloride, and tetracaine hydrochloride. It is found in products that reduce pain, itching, and stinging. The mix is also found in haemorrhoidal preparations and cough syrups. How can you avoid contact with this allergen? Avoid products that list any of the following names in the ingredients: • benzocaine • dibucaine hydrochloride • tetracaine hydrochloride • tetracaine-HCL • cinchocaine-HCL What are some products that may contain this allergen? Medications • Analgesics • Antiseptics • Hemorrhoid treatments • Lozenges for coughs and sore throat • Over-the-counter first aid treatments for pain and itching of injured skin • Prescription therapies for ear and eye inflammation • Sprays for coughs and sore throat For additional information about products that might contain this allergen, visit the Consumer Product Information Database (householdproducts.nlm.nih.gov) online at the United States National Library of Medicine. These lists are brief and provide just a few examples. They are not comprehensive. Product formulations also change frequently. Read product labels carefully and talk to your doctor if you have any questions. These are general guidelines. Talk to your doctor for more specific instructions. https://www.smartpracticecanada.com/shop/wa/style?id=LA525NA&m=SPAC 1/2 7-7-2020 Caine mix [A] | allergEAZE Contact Dermatitis Allergens https://www.smartpracticecanada.com/shop/wa/style?id=LA525NA&m=SPAC 2/2.
[Show full text]
Cardiovascular Tolerance and Safety of Intravenous Lidocaine in the Broiler
Louisiana State University LSU Digital Commons LSU Master's Theses Graduate School 2014 Cardiovascular tolerance and safety of intravenous lidocaine in the broiler chicken (Gallus gallus domesticus) Joao Manuel Lemos Brandao Louisiana State University and Agricultural and Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses Part of the Veterinary Medicine Commons Recommended Citation Lemos Brandao, Joao Manuel, "Cardiovascular tolerance and safety of intravenous lidocaine in the broiler chicken (Gallus gallus domesticus)" (2014). LSU Master's Theses. 690. https://digitalcommons.lsu.edu/gradschool_theses/690 This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact [email protected]. CARDIOVASCULAR TOLERANCE AND SAFETY OF INTRAVENOUS LIDOCAINE IN THE BROILER CHICKEN (GALLUS GALLUS DOMESTICUS) A Thesis Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Master of Science in The Interdepartmental Program of Veterinary Medical Sciences by João Manuel Lemos Brandão LMV, University of Trás-os-Montes e Alto Douro, Portugal May 2014 1 ACKNOWLEDGEMENTS For their guidance and support during the course of my Master of Science project I would like to thank Dr. Thomas N. Tully Jr., Dr. Anderson da Cunha, and Dr. Javier Nevarez. Completing the work described within this thesis would not have been possible without the assistance and support of Dr. Rhett Stout, faculty and staff of the Louisiana State University School of Veterinary Medicine (LSU-SVM), and interns and fellow House Officers of the LSU- SVM.
[Show full text]
Stembook 2018.Pdf
The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
[Show full text]